for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

NanoViricides Inc

NNVC.A

Latest Trade

3.88USD

Change

-0.02(-0.51%)

Volume

11,565

Today's Range

3.80

 - 

3.90

52 Week Range

1.85

 - 

19.20

As of on the NYSE MKT LLC ∙ Minimum 15 minute delay

Pricing

Previous Close
3.90
Open
3.86
Volume
11,565
3M AVG Volume
16.18
Today's High
3.90
Today's Low
3.80
52 Week High
19.20
52 Week Low
1.85
Shares Out (MIL)
10.65
Market Cap (MIL)
41.44
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

Altium Capital Management LP Reports 7.2% Passive Stake In Nanoviricides

Nanoviricides Inc Files For Mixed Shelf Of Up To $150.0 Million

Nanoviricides Inc Files For Offering 2.5 Million Shares Of Common Stock

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About NanoViricides Inc

NanoViricides, Inc. is a nano-biopharmaceutical research and development company. The Company is engaged the discovery, development, and commercialization of drugs to combat viral infections using its nanomedicines technology. The Company provides nanoviricide technology, which enables direct attacks at multiple points on a virus particle. The nanoviricide technology is engaged in both attacking extracellular virus thereby breaking the reinfection cycle, and simultaneously disrupting intracellular production of the virus, thereby enabling complete control of a virus infection. The nanoviricide technology also simultaneously enables attacking the intracellular reproduction of the virus by incorporating one or more active pharmaceutical ingredients (APIs) within the core of the nanoviricide. The Company’s lead product candidate is NV-HHV-101 in the HerpeCide program, as a skin cream for the treatment of shingles rash.

Industry

Biotechnology & Drugs

Contact Info

1 Controls Dr

SHELTON, CT

06484-6153

United States

+1.203.9376137

http://www.nanoviricides.com/

Executive Leadership

Anil Diwan

Chairman of the Board, President

Meeta Vyas

Chief Financial Officer

Stanley Glick

Independent Director

Makarand Jawadekar

Independent Director

Theodore Rokita

Independent Director

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
1.62
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
5.26
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-83.11
Return on Equity (TTM)
-71.98

Latest News

Latest News

BRIEF-Nanoviricides Files For Offering For Sale, Directly To Selected Investors, 1.4 Mln Shares Of Common Stock At $7.30 Per Share

* NANOVIRICIDES INC FILES FOR OFFERING FOR SALE, DIRECTLY TO SELECTED INVESTORS, 1.4 MILLION SHARES OF COMMON STOCK AT $7.30 PER SHARE Source text: [https://bit.ly/2Tszz8T] Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Nanoviricides Inc Files For Mixed Shelf Of Up To $150.0 Million

* NANOVIRICIDES INC FILES FOR MIXED SHELF OF UP TO $150.0 MILLION - SEC FILING Source text: (https://bit.ly/33KZ2yk) Further company coverage:

BRIEF-NanoViricides Inc Files For Non-Timely 10-Q

* NANOVIRICIDES INC FILES FOR NON-TIMELY 10-Q WITH U.S. SEC Source http://bit.ly/2k075Bb Further company coverage:

BRIEF-NanoViricides Says It Is Financially Stable

* NANOVIRICIDES PROVIDES UPDATE, SAYS COMPANY IS STABLE AND IS MOVING STEADILY TOWARDS CLINICAL TRIALS

BRIEF-Nanoviricides Inc Files For Non-Timely 10-Q

* NANOVIRICIDES INC FILES FOR NON-TIMELY 10-Q - SEC FILING Source text: (http://bit.ly/2Enapib) Further company coverage:

BRIEF-Nanoviricides Initiates a Safety/Toxicology Study of Its Leading Shingles Candidates

* NANOVIRICIDES - BEGUN INITIAL SAFETY, TOXICOLOGY EVALUATION OF CO'S NANOVIRICIDES DRUG CANDIDATES DEVELOPED AGAINST THE SHINGLES VIRUS VARICELLA-ZOSTER Source text for Eikon: Further company coverage:

BRIEF-Nanoviricides net loss $0.03/shr for three months ended Sept 30

* Nanoviricides Inc - net loss per common share for the three months ended September 30, 2017 was $0.03

BRIEF-Nanoviricides says ‍extended deal with Suny Upstate Medical Center to test nanoviricides drug candidates against varicella-zoster virus​

* Nanoviricides - extended deal with Suny Upstate Medical Center for further testing of Nanoviricides drug candidates against varicella-zoster virus

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up